Frequently Asked Questions
The market is segmented based on , By Product Type (Capsule, Tablet), Application (Epilepsy, Neuropathic Pain, Restless Legs Syndrome), Route of Administration (Oral, Parenteral, Intravenous), Mode of Purchase (Prescription, Retail and Over the Counter), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others) – Industry Trends and Forecast to 2030.
.
The Global Gabapentin Market size was valued at USD 2472.84 USD Million in 2022.
The Global Gabapentin Market is projected to grow at a CAGR of 2.6% during the forecast period of 2023 to 2030.
The major players operating in the market include Intas Pharmaceuticals Ltd, Glenmark, Alkem Labs, Marksans Pharma, Amneal Pharmaceuticals LLC, Jiangsu Nhwa Pharmaceutical Co., HENGRUI THERAPEUTICS , Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Novartis AG, Apotex , Arbor Pharmaceuticals LLC, Viatris , Teva Pharmaceuticals Ltd, Pfizer , Amgen , BristolMyers Squibb Company, Erytech Pharma, Rare Disease Therapeutics , Sanofi, Spectrum Pharmaceuticals , Takeda Pharmaceutical Company Limited, Genmab AS, Baxter, Gilead Sciences , CELGENE CORPORATION, Eisai Co., SymBio Pharmaceuticals Limited, Kiadis Pharma, OBI Pharma, Astellas Pharma , Medexus Pharma .
The market report covers data from the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
